Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …

Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …

Highlights•The epidermal growth factor (EGFR) is a therapeutic option for patients with all
RAS WT metastatic colorectal cancer (mCRC).•A better knowledge of the mechanism of …

2.1 Geltungsbereich und Zweck 2.1. 1. Zielsetzung und Fragestellung Das Kolorektale
Karzinom (KRK) ist mit etwa 64 000 Neuerkrankungen und ca. 26 000 Todesfällen pro Jahr …

Molecular subtypes-based therapies offer new potential framework for desired and precise
outcome in clinical settings. Current treatment strategies in colorectal cancer are largely 'one …

Tissue-based biopsy is the present main tool to explore the molecular landscape of cancer,
but it also has many limits to be frequently executed, being too invasive with the risk of side …

Importance The combination of a triple-drug chemotherapy regimen with an anti–epidermal
growth factor receptor (EGFR) agent as a first-line treatment of metastatic colorectal cancer …

Importance Few studies are available on the role of maintenance strategies after induction
treatment regimens based on anti–epidermal growth factor receptors, and the optimal …

Background Epidermal growth factor receptor (EGFR) inhibitors prevent cell growth and
have shown benefit in the treatment of metastatic colorectal cancer, whether used as single …

The prognosis of patients with metastatic colorectal cancer (mCRC) remain poor despite the
impressive improvement of treatments observed over the last 20 years that led to an …